Evidence map›Paper›PMID 32764548›Full record

ArticleScientific reports2020

Production and purification of higher molecular weight chondroitin by metabolically engineered Escherichia coli K4 strains.

S D'ambrosio, A Alfano, E Cassese, O F Restaino, S Barbuto Ferraiuolo, R Finamore, M Cammarota, C Schiraldi, D Cimini

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Biotechnology reports (Amsterdam, Netherlands) · 2022
    Article
  7. Heterologous production of chondroitin.Biotechnology reports (Amsterdam, Netherlands) · 2022
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

S D'ambrosioDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
A AlfanoDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
E CasseseDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
O F RestainoDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
S Barbuto FerraiuoloDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
R FinamoreDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
M CammarotaDepartment of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
C Schiraldi *Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy.
D Cimini *Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania L. Vanvitelli, via de Crecchio 7, 80138, Napoli, Italy. donatella.cimini@unicampania.it.
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The capsular polysaccharide obtained from Escherichia coli K4 is a glycosaminoglycan-like molecule, similar to chondroitin sulphate, that has established applications in the biomedical field. Recent efforts focused on the development of strategies to increase K4 polysaccharide fermentation titers up to technologically attractive levels, but an aspect that has not been investigated so far, is how changes in the molecular machinery that produces this biopolymer affect its molecular weight. In this work, we took advantage of recombinant E. coli K4 strains that overproduce capsular polysaccharide, to study whether the inferred pathway modifications also influenced the size of the produced polymer. Fed-batch fermentations were performed up to the 22 L scale, in potentially industrially applicable conditions, and a purification protocol that allows in particular the recovery of high molecular weight unsulphated chondroitin, was developed next. This approach allowed to determine the molecular weight of the purified polysaccharide, demonstrating that kfoF overexpression increased polymer size up to 133 kDa. Higher polysaccharide titers and size were also correlated to increased concentrations of UDP-GlcA and decreased concentrations of UDP-GalNAc during growth. These results are interesting also in view of novel potential applications of higher molecular weight chondroitin and chondroitin sulphate in the biomedical field.

Indexed as

Metabolic EngineeringBatch Cell Culture TechniquesChondroitinEscherichia coliFermentationFructoseHydrolysisMolecular WeightChondroitinFructose

Identifiers

PMID32764548
PMCPMC7411012
OpenAlexW3047530376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.